Community Health Systems (CYH) Financials

$2.82 -0.08 (-2.59%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$2.82 -0.01 (-0.35%)

As of 05/15/2026 04:20 PM Eastern

Annual Income Statements for Community Health Systems

This table shows Community Health Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	46	-133	-516
Consolidated Net Income / (Loss)	179	16	-362
Net Income / (Loss) Continuing Operations	179	16	-362
Total Pre-Tax Income	349	207	-283
Total Operating Income	821	957	542
Total Gross Profit	4,589	5,082	4,971
Total Revenue	12,211	12,490	12,634
Operating Revenue	12,211	12,490	12,634
Total Cost of Revenue	7,622	7,408	7,663
Operating Cost of Revenue	7,622	7,408	7,663
Total Operating Expenses	3,768	4,125	4,429
Selling, General & Admin Expense	3,336	3,388	3,642
Depreciation Expense	534	505	486
Other Operating Expenses / (Income)	-173	319	0.00
Impairment Charge	71	-87	301
Total Other Income / (Expense), net	-472	-750	-825
Interest Expense	-253	-72	-25
Interest & Investment Income	-844	-822	-850
Other Income / (Expense), net	119	0.00	0.00
Income Tax Expense	170	191	79
Net Income / (Loss) Attributable to Noncontrolling Interest	133	149	154
Basic Earnings per Share	$0.35	($1.02)	($3.90)
Weighted Average Basic Shares Outstanding	128.81M	130.45M	132.10M
Diluted Earnings per Share	$0.35	($1.02)	($3.90)
Weighted Average Diluted Shares Outstanding	130.06M	130.45M	132.10M
Weighted Average Basic & Diluted Shares Outstanding	134.70M	136.74M	138.92M

This table shows Community Health Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-42	415	-51	-38	-91	47	-41	-13	-391	-71	-13
Consolidated Net Income / (Loss)	0.00	447	-20	2.00	-52	86	-6.00	26	-355	-27	25
Net Income / (Loss) Continuing Operations	0.00	447	-20	2.00	-52	86	-6.00	26	-355	-27	25
Total Pre-Tax Income	70	324	6.00	40	-33	194	22	50	-419	64	67
Total Operating Income	204	228	210	246	173	328	231	238	-205	278	284
Total Gross Profit	1,181	969	1,155	1,273	1,259	1,395	1,285	1,255	1,262	1,169	1,298
Total Revenue	3,025	3,141	3,108	3,115	3,086	3,181	3,140	3,140	3,090	3,264	3,159
Operating Revenue	3,025	3,141	3,108	3,115	3,086	3,181	3,140	3,140	3,090	3,264	3,159
Total Cost of Revenue	1,844	2,172	1,953	1,842	1,827	1,786	1,855	1,885	1,828	2,095	1,861
Operating Cost of Revenue	1,844	2,172	1,953	1,842	1,827	1,786	1,855	1,885	1,828	2,095	1,861
Total Operating Expenses	977	741	945	1,027	1,086	1,067	1,054	1,017	1,467	891	1,014
Selling, General & Admin Expense	828	825	835	836	853	864	845	882	1,010	905	865
Depreciation Expense	137	136	132	124	128	121	115	125	117	129	105
Other Operating Expenses / (Income)	-35	-238	0.00	80	79	160	77	0.00	73	-150	68
Impairment Charge	47	18	-22	-13	26	-78	17	10	267	7.00	-24
Total Other Income / (Expense), net	-134	96	-204	-206	-206	-134	-209	-188	-214	-214	-217
Interest Expense	-78	-180	0.00	0.00	0.00	-72	0.00	-26	0.00	1.00	0.00
Interest & Investment Income	-212	-203	-204	-206	-206	-206	-209	-214	-214	-213	-217
Income Tax Expense	70	-123	26	38	19	108	28	24	-64	91	42
Net Income / (Loss) Attributable to Noncontrolling Interest	42	32	31	40	39	39	35	39	36	44	38
Basic Earnings per Share	($0.32)	$3.20	($0.40)	($0.29)	($0.69)	$0.36	($0.32)	($0.10)	($2.95)	($0.53)	($0.10)
Weighted Average Basic Shares Outstanding	129.14M	128.81M	129.69M	130.66M	130.70M	130.45M	131.27M	132.34M	132.38M	132.10M	132.88M
Diluted Earnings per Share	($0.32)	$3.20	($0.40)	($0.29)	($0.69)	$0.36	($0.32)	($0.10)	($2.95)	($0.53)	($0.10)
Weighted Average Diluted Shares Outstanding	129.14M	130.06M	129.69M	130.66M	130.70M	130.45M	131.27M	132.34M	132.38M	132.10M	132.88M
Weighted Average Basic & Diluted Shares Outstanding	134.71M	134.70M	136.74M	136.79M	136.80M	136.74M	138.97M	138.94M	138.95M	138.92M	140.31M

This table details how cash moves in and out of Community Health Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-389	-80	-1.00
Net Cash From Operating Activities	300	210	480
Net Cash From Continuing Operating Activities	300	210	480
Net Income / (Loss) Continuing Operations	179	16	-362
Consolidated Net Income / (Loss)	179	16	-362
Depreciation Expense	534	505	486
Non-Cash Adjustments To Reconcile Net Income	-99	44	481
Changes in Operating Assets and Liabilities, net	-314	-355	-125
Net Cash From Investing Activities	-259	-26	-275
Net Cash From Continuing Investing Activities	-259	-26	-275
Purchase of Property, Plant & Equipment	-415	-467	-360
Acquisitions	-28	-49	-34
Purchase of Investments	-114	-137	-81
Sale of Property, Plant & Equipment	38	28	5.00
Divestitures	89	432	174
Sale and/or Maturity of Investments	231	232	80
Other Investing Activities, net	-60	-65	-59
Net Cash From Financing Activities	-430	-264	-206
Net Cash From Continuing Financing Activities	-430	-264	-206
Repayment of Debt	-2,430	-4,327	-5,072
Payment of Dividends	-130	-142	-158
Issuance of Debt	2,125	4,204	5,024
Issuance of Common Equity	13	5.00	1.00
Other Financing Activities, net	-8.00	-4.00	-1.00
Cash Interest Paid	835	801	741
Cash Income Taxes Paid	-6.00	-91	-171

This table details how cash moves in and out of Community Health Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-46	-182	26	-26	-27	-53	10	-9.00	-6.00	4.00	394
Net Cash From Operating Activities	137	9.00	5.00	86	29	90	96	101	67	216	120
Net Cash From Continuing Operating Activities	137	9.00	5.00	86	29	90	96	101	67	216	120
Net Income / (Loss) Continuing Operations	1.00	446	-20	2.00	-52	86	-6.00	26	-354	-28	25
Consolidated Net Income / (Loss)	1.00	446	-20	2.00	-52	86	-6.00	26	-354	-28	25
Depreciation Expense	137	136	132	123	129	121	115	126	116	129	105
Non-Cash Adjustments To Reconcile Net Income	21	-234	26	37	76	-95	56	47	320	58	25
Changes in Operating Assets and Liabilities, net	-22	-339	-133	-76	-124	-22	-69	-98	-15	57	-35
Net Cash From Investing Activities	30	-52	-19	-86	-101	180	-99	-108	75	-143	444
Net Cash From Continuing Investing Activities	30	-52	-19	-86	-101	180	-99	-108	75	-143	444
Purchase of Property, Plant & Equipment	-93	-131	-122	-105	-130	-110	-93	-88	-70	-109	-85
Acquisitions	-15	-1.00	-13	-9.00	-21	-6.00	-5.00	-	-	-29	0.00
Purchase of Investments	-18	-41	-26	-73	-27	-11	-4.00	-19	-31	-27	-22
Sale of Property, Plant & Equipment	23	8.00	5.00	19	3.00	1.00	1.00	3.00	1.00	-	0.00
Divestitures	-	86	92	19	12	309	0.00	-	174	-	563
Sale and/or Maturity of Investments	142	48	61	76	84	11	12	20	22	26	23
Other Investing Activities, net	-9.00	-21	-16	-13	-22	-14	-10	-24	-21	-4.00	-35
Net Cash From Financing Activities	-213	-139	40	-26	45	-323	13	-2.00	-148	-69	-170
Net Cash From Continuing Financing Activities	-213	-139	40	-26	45	-323	13	-2.00	-148	-69	-170
Repayment of Debt	-190	-674	-757	-700	-695	-2,175	-885	-2,237	-806	-1,144	-1,088
Payment of Dividends	-33	-23	-45	-39	-25	-33	-50	-36	-38	-34	-35
Issuance of Debt	1.00	555	844	712	764	1,884	950	2,270	696	1,108	954
Issuance of Common Equity	9.00	3.00	2.00	1.00	1.00	1.00	0.00	1.00	-	-	0.00
Other Financing Activities, net	-	-	-4.00	-	-	-	-2.00	-	-	1.00	-1.00
Cash Interest Paid	204	221	197	188	198	218	149	211	202	179	229
Cash Income Taxes Paid	-	-	0.00	-37	-24	-30	0.00	-84	-48	-39	80

This table presents Community Health Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	14,669	14,455	14,054
Total Current Assets	3,082	3,208	3,301
Cash & Equivalents	118	38	37
Accounts Receivable	2,040	2,231	2,286
Inventories, net	353	328	331
Prepaid Expenses	237	260	236
Current Deferred & Refundable Income Taxes	99	76	53
Other Current Assets	235	275	358
Plant, Property, & Equipment, net	5,365	5,207	4,776
Plant, Property & Equipment, gross	9,639	9,511	9,160
Accumulated Depreciation	4,274	4,304	4,384
Total Noncurrent Assets	6,222	6,040	5,977
Goodwill	4,166	3,958	3,789
Noncurrent Deferred & Refundable Income Taxes	49	29	13
Other Noncurrent Operating Assets	2,007	2,053	2,175
Total Liabilities & Shareholders' Equity	14,669	14,455	14,054
Total Liabilities	15,403	15,279	15,371
Total Current Liabilities	2,186	2,142	2,345
Short-Term Debt	21	21	20
Accounts Payable	773	912	913
Accrued Expenses	418	354	479
Current Employee Benefit Liabilities	637	571	596
Other Current Liabilities	148	124	115
Other Current Nonoperating Liabilities	189	160	222
Total Noncurrent Liabilities	13,217	13,137	13,026
Long-Term Debt	11,614	11,466	11,432
Noncurrent Deferred & Payable Income Tax Liabilities	354	369	231
Other Noncurrent Operating Liabilities	1,249	1,302	1,363
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	541	323	359
Total Equity & Noncontrolling Interests	-1,275	-1,147	-1,676
Total Preferred & Common Equity	-1,367	-1,392	-1,914
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-1,367	-1,392	-1,914
Common Stock	2,085	2,186	2,176
Retained Earnings	-3,431	-3,564	-4,080
Accumulated Other Comprehensive Income / (Loss)	-21	-14	-10
Noncontrolling Interest	92	245	238

This table presents Community Health Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	14,914	14,623	14,648	14,674	14,417	14,411	13,905	13,890
Total Current Assets	3,269	3,114	3,192	3,248	3,175	3,199	3,108	3,407
Cash & Equivalents	300	144	118	91	48	39	33	431
Accounts Receivable	1,969	2,043	2,043	2,160	2,194	2,195	2,043	2,326
Inventories, net	355	345	333	325	329	337	311	328
Prepaid Expenses	246	276	259	249	263	244	227	261
Current Deferred & Refundable Income Taxes	98	79	100	98	34	92	92	0.00
Other Current Assets	301	227	339	325	307	292	402	61
Plant, Property, & Equipment, net	5,450	5,255	5,250	5,160	5,219	5,222	4,964	4,742
Plant, Property & Equipment, gross	9,727	9,560	9,527	9,367	9,607	9,594	9,094	9,200
Accumulated Depreciation	4,277	4,305	4,277	4,207	4,388	4,372	4,130	4,458
Total Noncurrent Assets	6,195	6,254	6,206	6,266	6,023	5,990	5,833	5,741
Goodwill	4,201	4,051	4,054	3,943	3,957	3,972	3,940	3,785
Noncurrent Deferred & Refundable Income Taxes	53	49	49	49	29	29	29	13
Other Noncurrent Operating Assets	1,941	2,154	2,103	2,274	2,037	1,989	1,864	1,943
Total Liabilities & Shareholders' Equity	14,914	14,623	14,648	14,674	14,417	14,411	13,905	13,890
Total Liabilities	16,092	15,414	15,468	15,567	15,295	15,290	15,175	15,219
Total Current Liabilities	2,383	2,132	2,076	2,149	2,136	2,172	2,126	2,370
Short-Term Debt	21	39	30	22	34	27	20	29
Accounts Payable	820	712	736	837	941	896	842	974
Accrued Expenses	572	463	427	472	335	378	493	483
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	96
Current Employee Benefit Liabilities	601	596	560	513	504	499	460	478
Other Current Liabilities	151	138	134	121	115	114	113	112
Other Current Nonoperating Liabilities	218	184	189	184	207	258	198	198
Total Noncurrent Liabilities	13,709	13,282	13,392	13,418	13,159	13,118	13,049	12,849
Long-Term Debt	11,943	11,696	11,728	11,820	11,533	11,504	11,467	11,303
Capital Lease Obligations	563	588	580	560	546	-	528	535
Noncurrent Deferred & Payable Income Tax Liabilities	477	351	362	344	354	351	239	205
Other Noncurrent Operating Liabilities	726	647	722	694	726	1,263	815	806
Redeemable Noncontrolling Interest	516	561	583	329	329	324	322	364
Total Equity & Noncontrolling Interests	-1,694	-1,352	-1,403	-1,222	-1,207	-1,203	-1,592	-1,693
Total Preferred & Common Equity	-1,786	-1,445	-1,489	-1,463	-1,428	-1,441	-1,823	-1,923
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,786	-1,445	-1,489	-1,463	-1,428	-1,441	-1,823	-1,923
Common Stock	2,092	2,055	2,050	2,171	2,193	2,191	2,195	2,177
Retained Earnings	-3,845	-3,482	-3,520	-3,611	-3,605	-3,619	-4,010	-4,093
Accumulated Other Comprehensive Income / (Loss)	-33	-18	-19	-23	-16	-13	-8.00	-7.00
Noncontrolling Interest	92	93	86	241	221	238	231	230

This table displays calculated financial ratios and metrics derived from Community Health Systems' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-1.27%	2.28%	1.15%
EBITDA Growth	-24.10%	-0.81%	-29.69%
EBIT Growth	-32.95%	1.81%	-43.36%
NOPAT Growth	-59.27%	-82.43%	412.90%
Net Income Growth	-51.36%	-91.06%	-2,362.50%
EPS Growth	-80.11%	-391.43%	-282.35%
Operating Cash Flow Growth	329.01%	-30.00%	128.57%
Free Cash Flow Firm Growth	213.04%	-74.71%	223.56%
Invested Capital Growth	-5.28%	-1.70%	-4.31%
Revenue Q/Q Growth	-0.75%	0.32%	0.66%
EBITDA Q/Q Growth	-4.60%	6.17%	-3.93%
EBIT Q/Q Growth	-7.39%	11.67%	-8.45%
NOPAT Q/Q Growth	320.96%	-92.28%	-8.45%
Net Income Q/Q Growth	489.13%	-95.76%	-45.38%
EPS Q/Q Growth	123.81%	-156.04%	-29.57%
Operating Cash Flow Q/Q Growth	225.00%	62.79%	35.59%
Free Cash Flow Firm Q/Q Growth	166.91%	-58.16%	-23.68%
Invested Capital Q/Q Growth	-2.62%	-7.04%	-5.41%
Profitability Metrics	-	-	-
Gross Margin	37.58%	40.69%	39.35%
EBITDA Margin	12.07%	11.71%	8.14%
Operating Margin	6.72%	7.66%	4.29%
EBIT Margin	7.70%	7.66%	4.29%
Profit (Net Income) Margin	1.47%	0.13%	-2.87%
Tax Burden Percent	51.29%	7.73%	127.92%
Interest Burden Percent	37.13%	21.63%	-52.21%
Effective Tax Rate	48.71%	92.27%	0.00%
Return on Invested Capital (ROIC)	3.73%	0.68%	3.60%
ROIC Less NNEP Spread (ROIC-NNEP)	1.72%	0.18%	-2.78%
Return on Net Nonoperating Assets (RNNOA)	-26.92%	-2.73%	30.22%
Return on Equity (ROE)	-23.19%	-2.05%	33.82%
Cash Return on Invested Capital (CROIC)	9.15%	2.40%	8.00%
Operating Return on Assets (OROA)	6.29%	6.57%	3.80%
Return on Assets (ROA)	1.20%	0.11%	-2.54%
Return on Common Equity (ROCE)	-41.13%	-3.64%	52.22%
Return on Equity Simple (ROE_SIMPLE)	-13.09%	-1.15%	18.91%
Net Operating Profit after Tax (NOPAT)	421	74	379
NOPAT Margin	3.45%	0.59%	3.00%
Net Nonoperating Expense Percent (NNEP)	2.01%	0.50%	6.38%
Return On Investment Capital (ROIC_SIMPLE)	4.06%	0.72%	3.88%
Cost of Revenue to Revenue	62.42%	59.31%	60.65%
SG&A Expenses to Revenue	27.32%	27.13%	28.83%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	30.86%	33.03%	35.06%
Earnings before Interest and Taxes (EBIT)	940	957	542
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,474	1,462	1,028
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.05	0.03	0.03
Price to Earnings (P/E)	12.65	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	7.90%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.16	1.15	1.20
Enterprise Value to Revenue (EV/Rev)	1.04	1.00	0.98
Enterprise Value to EBITDA (EV/EBITDA)	8.64	8.51	12.09
Enterprise Value to EBIT (EV/EBIT)	13.54	13.00	22.93
Enterprise Value to NOPAT (EV/NOPAT)	30.24	168.24	32.76
Enterprise Value to Operating Cash Flow (EV/OCF)	42.44	59.26	25.89
Enterprise Value to Free Cash Flow (EV/FCFF)	12.34	47.69	14.72
Leverage & Solvency	-	-	-
Debt to Equity	-15.85	-13.94	-8.70
Long-Term Debt to Equity	-15.82	-13.92	-8.68
Financial Leverage	-15.61	-14.96	-10.86
Leverage Ratio	-19.36	-18.69	-13.32
Compound Leverage Factor	-7.19	-4.04	6.95
Debt to Total Capital	106.73%	107.73%	112.99%
Short-Term Debt to Total Capital	0.19%	0.20%	0.20%
Long-Term Debt to Total Capital	106.54%	107.53%	112.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	5.81%	5.33%	5.89%
Common Equity to Total Capital	-12.54%	-13.05%	-18.89%
Debt to EBITDA	7.89	7.86	11.14
Net Debt to EBITDA	7.81	7.83	11.10
Long-Term Debt to EBITDA	7.88	7.84	11.12
Debt to NOPAT	27.63	155.29	30.18
Net Debt to NOPAT	27.35	154.78	30.09
Long-Term Debt to NOPAT	27.58	155.01	30.13
Altman Z-Score	0.81	0.84	0.72
Noncontrolling Interest Sharing Ratio	-77.40%	-77.09%	-54.41%
Liquidity Ratios	-	-	-
Current Ratio	1.41	1.50	1.41
Quick Ratio	0.99	1.06	0.99
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	1,032	261	844
Operating Cash Flow to CapEx	79.58%	47.84%	135.21%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.82	0.86	0.89
Accounts Receivable Turnover	5.95	5.85	5.59
Inventory Turnover	21.53	21.76	23.26
Fixed Asset Turnover	2.24	2.36	2.53
Accounts Payable Turnover	9.51	8.79	8.40
Days Sales Outstanding (DSO)	61.31	62.41	65.25
Days Inventory Outstanding (DIO)	16.95	16.78	15.69
Days Payable Outstanding (DPO)	38.38	41.51	43.46
Cash Conversion Cycle (CCC)	39.88	37.67	37.48
Capital & Investment Metrics	-	-	-
Invested Capital	10,972	10,785	10,320
Invested Capital Turnover	1.08	1.15	1.20
Increase / (Decrease) in Invested Capital	-611	-187	-465
Enterprise Value (EV)	12,732	12,445	12,427
Market Capitalization	582	428	415
Book Value per Share	($10.15)	($10.18)	($13.77)
Tangible Book Value per Share	($41.07)	($39.11)	($41.04)
Total Capital	10,901	10,663	10,135
Total Debt	11,635	11,487	11,452
Total Long-Term Debt	11,614	11,466	11,432
Net Debt	11,517	11,449	11,415
Capital Expenditures (CapEx)	377	439	355
Debt-free, Cash-free Net Working Capital (DFCFNWC)	799	1,049	939
Debt-free Net Working Capital (DFNWC)	917	1,087	976
Net Working Capital (NWC)	896	1,066	956
Net Nonoperating Expense (NNE)	242	58	741
Net Nonoperating Obligations (NNO)	11,706	11,609	11,637
Total Depreciation and Amortization (D&A)	534	505	486
Debt-free, Cash-free Net Working Capital to Revenue	6.54%	8.40%	7.43%
Debt-free Net Working Capital to Revenue	7.51%	8.70%	7.73%
Net Working Capital to Revenue	7.34%	8.53%	7.57%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.35	($1.02)	($3.90)
Adjusted Weighted Average Basic Shares Outstanding	128.81M	130.45M	132.10M
Adjusted Diluted Earnings per Share	$0.35	($1.02)	($3.90)
Adjusted Weighted Average Diluted Shares Outstanding	130.06M	130.45M	132.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	134.70M	136.74M	138.92M
Normalized Net Operating Profit after Tax (NOPAT)	458	609	590
Normalized NOPAT Margin	3.75%	4.88%	4.67%
Pre Tax Income Margin	2.86%	1.66%	-2.24%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	72.63%	887.50%	-43.65%
Augmented Payout Ratio	72.63%	887.50%	-43.65%

This table displays calculated financial ratios and metrics derived from Community Health Systems' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.89%	-2.85%	-0.10%	6.17%	2.02%	1.27%	1.03%	0.80%	0.13%	2.61%	0.61%
EBITDA Growth	-28.36%	-34.30%	-14.07%	46.43%	-11.44%	23.35%	1.17%	-1.36%	-129.47%	-9.35%	12.43%
EBIT Growth	-40.00%	-45.97%	-22.22%	106.72%	-15.20%	43.86%	10.00%	-3.25%	-218.50%	-15.24%	22.94%
NOPAT Growth	-100.00%	-26.13%	-558.02%	-85.23%	0.00%	-53.78%	91.00%	906.18%	-218.50%	-180.66%	268.21%
Net Income Growth	-100.00%	101.35%	-166.67%	100.67%	0.00%	-80.76%	70.00%	1,200.00%	-582.69%	-131.40%	516.67%
EPS Growth	-137.65%	131.88%	-3,900.00%	88.49%	-115.63%	-88.75%	20.00%	65.52%	-327.54%	-247.22%	68.75%
Operating Cash Flow Growth	14.17%	101.69%	-95.05%	62.26%	-78.83%	900.00%	1,820.00%	17.44%	131.03%	140.00%	25.00%
Free Cash Flow Firm Growth	-929.84%	160.85%	5.82%	95.17%	84.18%	-64.09%	109.85%	1,211.97%	356.43%	4.61%	939.10%
Invested Capital Growth	13.64%	-5.28%	4.21%	0.77%	2.97%	-1.70%	-1.54%	-6.20%	-5.96%	-4.31%	-9.56%
Revenue Q/Q Growth	3.10%	3.83%	-1.05%	0.23%	-0.93%	3.08%	-1.29%	0.00%	-1.59%	5.63%	-3.22%
EBITDA Q/Q Growth	35.32%	6.74%	-6.04%	7.89%	-18.16%	48.68%	-22.94%	5.20%	-124.45%	557.30%	-4.42%
EBIT Q/Q Growth	71.43%	11.76%	-7.89%	17.14%	-29.67%	89.60%	-29.57%	3.03%	-186.13%	235.61%	2.16%
NOPAT Q/Q Growth	-100.00%	0.00%	-322.54%	101.76%	884.55%	20.07%	-143.33%	296.44%	-215.95%	18.27%	190.36%
Net Income Q/Q Growth	100.00%	0.00%	-104.47%	110.00%	-2,700.00%	265.38%	-106.98%	533.33%	-1,465.38%	92.39%	192.59%
EPS Q/Q Growth	87.30%	1,100.00%	-112.50%	27.50%	-137.93%	152.17%	-188.89%	68.75%	-2,850.00%	82.03%	81.13%
Operating Cash Flow Q/Q Growth	158.49%	-93.43%	-44.44%	1,620.00%	-66.28%	210.34%	6.67%	5.21%	-33.66%	222.39%	-44.44%
Free Cash Flow Firm Q/Q Growth	13.81%	168.46%	-226.19%	93.52%	-182.56%	255.40%	-65.40%	631.97%	-34.84%	-36.61%	243.66%
Invested Capital Q/Q Growth	-2.03%	-2.62%	5.47%	0.15%	0.11%	-7.04%	5.65%	-4.59%	0.36%	-5.41%	-0.15%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	39.04%	30.85%	37.16%	40.87%	40.80%	43.85%	40.92%	39.97%	40.84%	35.82%	41.09%
EBITDA Margin	11.27%	11.59%	11.00%	11.85%	9.79%	14.12%	11.02%	11.59%	-2.88%	12.47%	12.31%
Operating Margin	6.74%	7.26%	6.76%	7.90%	5.61%	10.31%	7.36%	7.58%	-6.63%	8.52%	8.99%
EBIT Margin	6.74%	7.26%	6.76%	7.90%	5.61%	10.31%	7.36%	7.58%	-6.63%	8.52%	8.99%
Profit (Net Income) Margin	0.00%	14.23%	-0.64%	0.06%	-1.69%	2.70%	-0.19%	0.83%	-11.49%	-0.83%	0.79%
Tax Burden Percent	0.00%	137.96%	-333.33%	5.00%	157.58%	44.33%	-27.27%	52.00%	84.73%	-42.19%	37.31%
Interest Burden Percent	34.31%	142.11%	2.86%	16.26%	-19.08%	59.15%	9.52%	21.01%	204.39%	23.02%	23.59%
Effective Tax Rate	100.00%	-37.96%	433.33%	95.00%	0.00%	55.67%	127.27%	48.00%	0.00%	142.19%	62.69%
Return on Invested Capital (ROIC)	0.00%	10.84%	-24.25%	0.42%	4.27%	5.25%	-2.19%	4.40%	-5.18%	-4.30%	3.91%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	11.94%	-18.65%	0.34%	2.88%	4.74%	-1.73%	3.59%	-6.89%	-3.53%	3.23%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-186.40%	281.34%	-4.33%	-34.74%	-70.91%	25.46%	-51.11%	78.63%	38.27%	-35.04%
Return on Equity (ROE)	0.00%	-175.56%	257.09%	-3.90%	-30.46%	-65.66%	23.28%	-46.71%	73.45%	33.97%	-31.13%
Cash Return on Invested Capital (CROIC)	-14.56%	9.15%	-1.26%	6.74%	5.45%	2.40%	2.70%	8.40%	9.83%	8.00%	13.88%
Operating Return on Assets (OROA)	5.43%	5.93%	5.52%	6.59%	4.72%	8.84%	6.34%	6.55%	-5.83%	7.55%	8.04%
Return on Assets (ROA)	0.00%	11.63%	-0.53%	0.05%	-1.42%	2.32%	-0.16%	0.72%	-10.09%	-0.73%	0.71%
Return on Common Equity (ROCE)	0.00%	-311.44%	453.02%	-6.37%	-47.79%	-116.28%	40.07%	-80.55%	111.59%	52.46%	-47.26%
Return on Equity Simple (ROE_SIMPLE)	2.58%	0.00%	-8.93%	-28.81%	-25.77%	0.00%	-2.10%	-3.75%	13.66%	0.00%	17.21%
Net Operating Profit after Tax (NOPAT)	0.00	315	-700	12	121	145	-63	124	-144	-117	106
NOPAT Margin	0.00%	10.01%	-22.52%	0.39%	3.92%	4.57%	-2.01%	3.94%	-4.64%	-3.59%	3.35%
Net Nonoperating Expense Percent (NNEP)	0.00%	-1.10%	-5.60%	0.08%	1.39%	0.51%	-0.46%	0.81%	1.71%	-0.78%	0.68%
Return On Investment Capital (ROIC_SIMPLE)	-	3.04%	-	-	-	1.41%	-	-	-	-1.20%	1.04%
Cost of Revenue to Revenue	60.96%	69.15%	62.84%	59.13%	59.20%	56.15%	59.08%	60.03%	59.16%	64.19%	58.91%
SG&A Expenses to Revenue	27.37%	26.27%	26.87%	26.84%	27.64%	27.16%	26.91%	28.09%	32.69%	27.73%	27.38%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	32.30%	23.59%	30.41%	32.97%	35.19%	33.54%	33.57%	32.39%	47.48%	27.30%	32.10%
Earnings before Interest and Taxes (EBIT)	204	228	210	246	173	328	231	238	-205	278	284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	341	364	342	369	302	449	346	364	-89	407	389
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.02	0.05	0.05	0.05	0.03	0.03	0.04	0.04	0.07	0.03	0.03
Price to Earnings (P/E)	0.00	12.65	0.00	2.12	1.69	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	7.90%	0.00%	47.20%	59.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.16	1.16	1.17	1.16	1.14	1.15	1.15	1.15	1.23	1.20	1.20
Enterprise Value to Revenue (EV/Rev)	1.07	1.04	1.11	1.09	1.07	1.00	1.05	1.00	1.07	0.98	0.98
Enterprise Value to EBITDA (EV/EBITDA)	8.49	8.64	10.39	9.53	9.64	8.51	8.93	8.57	12.50	12.09	11.58
Enterprise Value to EBIT (EV/EBIT)	12.93	13.54	17.73	15.19	15.49	13.00	13.39	12.91	22.60	22.93	20.85
Enterprise Value to NOPAT (EV/NOPAT)	0.00	30.24	41.51	15.58	13.85	168.24	99.52	55.70	32.28	32.76	29.78
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	42.44	66.14	56.92	102.93	59.26	43.50	39.62	37.79	25.89	24.61
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	12.34	0.00	17.34	21.29	47.69	42.30	13.28	12.09	14.72	8.24
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-10.63	-15.85	-15.58	-15.05	-13.89	-13.94	-13.80	-13.12	-9.46	-8.70	-8.93
Long-Term Debt to Equity	-10.62	-15.82	-15.53	-15.01	-13.86	-13.92	-13.76	-13.09	-9.44	-8.68	-8.91
Financial Leverage	-10.73	-15.61	-15.08	-12.67	-12.04	-14.96	-14.76	-14.22	-11.41	-10.86	-10.83
Leverage Ratio	-14.04	-19.36	-18.56	-15.02	-14.29	-18.69	-17.40	-17.10	-13.21	-13.32	-12.83
Compound Leverage Factor	-4.82	-27.51	-0.53	-2.44	2.73	-11.06	-1.66	-3.59	-27.01	-3.07	-3.03
Debt to Total Capital	110.38%	106.73%	106.86%	107.12%	107.76%	107.73%	107.81%	108.25%	111.82%	112.99%	112.61%
Short-Term Debt to Total Capital	0.19%	0.19%	0.34%	0.26%	0.19%	0.20%	0.30%	0.25%	0.19%	0.20%	0.28%
Long-Term Debt to Total Capital	110.19%	106.54%	106.52%	106.86%	107.57%	107.53%	107.51%	108.00%	111.63%	112.80%	112.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	5.36%	5.81%	5.67%	5.81%	4.95%	5.33%	4.90%	5.28%	5.15%	5.89%	5.64%
Common Equity to Total Capital	-15.74%	-12.54%	-12.53%	-12.93%	-12.71%	-13.05%	-12.71%	-13.53%	-16.97%	-18.89%	-18.25%
Debt to EBITDA	8.11	7.89	9.49	8.71	9.01	7.86	8.26	7.89	11.23	11.14	11.08
Net Debt to EBITDA	7.91	7.81	9.38	8.63	8.94	7.83	8.23	7.87	11.20	11.10	10.68
Long-Term Debt to EBITDA	8.09	7.88	9.46	8.69	8.99	7.84	8.24	7.87	11.21	11.12	11.05
Debt to NOPAT	-65.73	27.63	37.91	14.25	12.94	155.29	92.07	51.29	28.99	30.18	28.49
Net Debt to NOPAT	-64.16	27.35	37.47	14.11	12.84	154.78	91.70	51.12	28.91	30.09	27.46
Long-Term Debt to NOPAT	-65.62	27.58	37.79	14.22	12.91	155.01	91.81	51.17	28.95	30.13	28.42
Altman Z-Score	0.59	0.65	0.66	0.68	0.65	0.70	0.68	0.68	0.57	0.66	0.67
Noncontrolling Interest Sharing Ratio	-54.36%	-77.40%	-76.21%	-63.25%	-56.88%	-77.09%	-72.14%	-72.45%	-51.92%	-54.41%	-51.84%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.37	1.41	1.46	1.54	1.51	1.50	1.49	1.47	1.46	1.41	1.44
Quick Ratio	0.95	0.99	1.03	1.04	1.05	1.06	1.05	1.03	0.98	0.99	1.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,352	926	-1,168	-76	-214	332	115	842	549	348	1,195
Operating Cash Flow to CapEx	195.71%	7.32%	4.27%	100.00%	22.83%	82.57%	104.35%	118.82%	97.10%	198.17%	141.18%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	347.72	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	216.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	107.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.82	0.82	0.83	0.84	0.86	0.86	0.86	0.88	0.89	0.89
Accounts Receivable Turnover	6.16	5.95	5.92	6.13	6.03	5.85	5.91	5.92	5.97	5.59	5.60
Inventory Turnover	21.00	21.53	21.30	21.75	21.99	21.76	21.69	21.95	23.13	23.26	23.35
Fixed Asset Turnover	2.27	2.24	2.26	2.30	2.35	2.36	2.39	2.40	2.48	2.53	2.54
Accounts Payable Turnover	9.23	9.51	9.67	9.56	9.02	8.79	8.84	9.01	8.76	8.40	8.01
Days Sales Outstanding (DSO)	59.23	61.31	61.62	59.57	60.53	62.41	61.75	61.64	61.11	65.25	65.19
Days Inventory Outstanding (DIO)	17.38	16.95	17.14	16.78	16.60	16.78	16.83	16.63	15.78	15.69	15.63
Days Payable Outstanding (DPO)	39.53	38.38	37.73	38.19	40.44	41.51	41.27	40.51	41.67	43.46	45.57
Cash Conversion Cycle (CCC)	37.08	39.88	41.02	38.17	36.68	37.67	37.31	37.77	35.23	37.48	35.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	11,267	10,972	11,572	11,589	11,602	10,785	11,394	10,871	10,910	10,320	10,305
Invested Capital Turnover	1.16	1.08	1.08	1.07	1.09	1.15	1.09	1.12	1.12	1.20	1.17
Increase / (Decrease) in Invested Capital	1,352	-611	468	88	335	-187	-178	-718	-692	-465	-1,089
Enterprise Value (EV)	13,125	12,732	13,493	13,491	13,278	12,445	13,094	12,521	13,378	12,427	12,405
Market Capitalization	290	582	660	602	397	428	479	467	843	415	375
Book Value per Share	($13.26)	($10.15)	($10.73)	($10.89)	($10.69)	($10.18)	($10.88)	($10.37)	($13.12)	($13.77)	($13.84)
Tangible Book Value per Share	($44.44)	($41.07)	($40.80)	($40.54)	($39.52)	($39.11)	($41.02)	($38.95)	($41.48)	($41.04)	($41.09)
Total Capital	11,349	10,901	11,532	11,518	11,509	10,663	11,235	10,652	10,745	10,135	10,538
Total Debt	12,527	11,635	12,323	12,338	12,402	11,487	12,113	11,531	12,015	11,452	11,867
Total Long-Term Debt	12,506	11,614	12,284	12,308	12,380	11,466	12,079	11,504	11,995	11,432	11,838
Net Debt	12,227	11,517	12,179	12,220	12,311	11,449	12,065	11,492	11,982	11,415	11,436
Capital Expenditures (CapEx)	70	123	117	86	127	109	92	85	69	109	85
Debt-free, Cash-free Net Working Capital (DFCFNWC)	607	799	877	1,028	1,030	1,049	1,025	1,015	969	939	635
Debt-free Net Working Capital (DFNWC)	907	917	1,021	1,146	1,121	1,087	1,073	1,054	1,002	976	1,066
Net Working Capital (NWC)	886	896	982	1,116	1,099	1,066	1,039	1,027	982	956	1,037
Net Nonoperating Expense (NNE)	0.00	-132	-680	10	173	59	-57	98	212	-90	81
Net Nonoperating Obligations (NNO)	12,445	11,706	12,363	12,409	12,495	11,609	12,272	11,750	12,180	11,637	11,634
Total Depreciation and Amortization (D&A)	137	136	132	123	129	121	115	126	116	129	105
Debt-free, Cash-free Net Working Capital to Revenue	4.93%	6.54%	7.18%	8.30%	8.27%	8.40%	8.19%	8.09%	7.72%	7.43%	5.02%
Debt-free Net Working Capital to Revenue	7.37%	7.51%	8.36%	9.25%	9.00%	8.70%	8.57%	8.40%	7.98%	7.73%	8.42%
Net Working Capital to Revenue	7.20%	7.34%	8.04%	9.01%	8.83%	8.53%	8.30%	8.19%	7.82%	7.57%	8.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.32)	$3.20	($0.40)	($0.29)	($0.69)	$0.36	($0.32)	($0.10)	($2.95)	($0.53)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	129.14M	128.81M	129.69M	130.66M	130.70M	130.45M	131.27M	132.34M	132.38M	132.10M	132.88M
Adjusted Diluted Earnings per Share	($0.32)	$3.20	($0.40)	($0.29)	($0.69)	$0.36	($0.32)	($0.10)	($2.95)	($0.53)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	129.14M	130.06M	129.69M	130.66M	130.70M	130.45M	131.27M	132.34M	132.38M	132.10M	132.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	134.71M	134.70M	136.74M	136.79M	136.80M	136.74M	138.97M	138.94M	138.95M	138.92M	140.31M
Normalized Net Operating Profit after Tax (NOPAT)	176	172	132	163	139	175	174	129	43	200	182
Normalized NOPAT Margin	5.81%	5.48%	4.23%	5.24%	4.51%	5.50%	5.53%	4.11%	1.40%	6.11%	5.76%
Pre Tax Income Margin	2.31%	10.32%	0.19%	1.28%	-1.07%	6.10%	0.70%	1.59%	-13.56%	1.96%	2.12%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	278.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-117.28	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	169.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-226.28	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-319.57%	72.63%	113.18%	32.63%	35.01%	887.50%	490.00%	266.67%	-63.05%	-43.65%	-43.20%
Augmented Payout Ratio	-319.57%	72.63%	113.18%	32.63%	35.01%	887.50%	490.00%	266.67%	-63.05%	-43.65%	-43.20%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Community Health Systems (NYSE: CYH) quarterly filings over the last four years, focusing on trends in cash flow, income, and the balance sheet. Items are sorted with positives first, then neutral points, then negatives.

Consistently positive operating cash flow in 2024–Q1 2025, with Net Cash From Continuing Operating Activities around $120M (Q1 2025), $216M (Q4 2024), $101M (Q2 2024), and $96M (Q1 2024).
Q1 2025 net income from continuing operations turned positive, about $25M, signaling a potential move toward profitability.
Q1 2025 gross margin improved to roughly 41% (Gross Profit ≈ $1.298B on Operating Revenue ≈ $3.159B), up from lower margins in some prior quarters (e.g., Q4 2024 ≈ 36%).
Material divestiture proceeds have supplied meaningful liquidity in multiple quarters (e.g., $563M in Q1 2025; $309M in Q4 2024; $174M in Q3 2024; $309M in Q4 2023).
Revenue generally sits in the low-to-mid $3B range across the period, indicating stability but limited growth.
The company has accessed debt markets to support liquidity, including debt issuances of about $954M (Q1 2025), $1.108B (Q4 2024), and $696M (Q3 2024), which improves near-term liquidity but adds leverage.
High leverage and negative book value: Long-term debt around $11.3B–$11.9B, total liabilities near $15.2B, and equity often negative (e.g., Total Common Equity around -$1.9B in recent periods).
Significant impairment charges and recurring net losses in several quarters, including impairment of $267M in 2024 Q3 and substantial negative net income across multiple quarters, though performance improves in isolated quarters (e.g., Q1 2025).

05/17/26 07:24 PM ETAI Generated. May Contain Errors.

Community Health Systems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Community Health Systems' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Community Health Systems' net income appears to be on an upward trend, with a most recent value of -$362 million in 2024, falling from $179 million in 2022. The previous period was $16 million in 2023. Find out what analysts predict for Community Health Systems in the coming months.

Community Health Systems' total operating income in 2024 was $542 million, based on the following breakdown:

Total Gross Profit: $4.97 billion
Total Operating Expenses: $4.43 billion

Over the last 2 years, Community Health Systems' total revenue changed from $12.21 billion in 2022 to $12.63 billion in 2024, a change of 3.5%.

Community Health Systems' total liabilities were at $15.37 billion at the end of 2024, a 0.6% increase from 2023, and a 0.2% decrease since 2022.

In the past 2 years, Community Health Systems' cash and equivalents has ranged from $37 million in 2024 to $118 million in 2022, and is currently $37 million as of their latest financial filing in 2024.

Over the last 2 years, Community Health Systems' book value per share changed from -10.15 in 2022 to -13.77 in 2024, a change of 35.7%.

Related Companies

Financial statements for NYSE:CYH last updated on 4/26/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Community Health Systems (CYH) Financials

Financials Breakdown Chart

Key Financial Trends

Community Health Systems Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Community Health Systems (CYH) Financials

Annual Income Statements for Community Health Systems

Quarterly Income Statements for Community Health Systems

Annual Cash Flow Statements for Community Health Systems

Quarterly Cash Flow Statements for Community Health Systems

Annual Balance Sheets for Community Health Systems

Quarterly Balance Sheets for Community Health Systems

Annual Metrics And Ratios for Community Health Systems

Quarterly Metrics And Ratios for Community Health Systems

Financials Breakdown Chart

Key Financial Trends

Community Health Systems Financials - Frequently Asked Questions

When does Community Health Systems' fiscal year end?

How has Community Health Systems' net income changed over the last 2 years?

What is Community Health Systems' operating income?

How has Community Health Systems' revenue changed over the last 2 years?

How much debt does Community Health Systems have?

How much cash does Community Health Systems have?

How has Community Health Systems' book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools